Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Inebilizumab by Amgen for Myasthenia Gravis: Likelihood of Approval
Inebilizumab is under clinical development by Amgen and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III...
Data Insights
Inebilizumab by Amgen for Immunoglobulin G4-Related Disease (IgG4-RD): Likelihood of Approval
Inebilizumab is under clinical development by Amgen and currently in Phase III for Immunoglobulin G4-Related Disease (IgG4-RD). According to GlobalData,...